Physician profile
Phalgoon Shah
NPI 1821409319
$3,971.55
in general payments reported to CMS, 2019-2025
34 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $682 · 2021: $872 · 2022: $256 · 2023: $535 · 2024: $629 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.62 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $977.03 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $597.95 | 2020-2025 | Tezspire, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.58 | 2020-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $169.55 | 2021-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $150.04 | 2020-2024 | Opsumit, Uptravi |
| Insmed, INC. | $148.52 | 2019-2025 | Brinsupri, Arikayce |
| Mallinckrodt Hospital Products INC. | $139.20 | 2020-2025 | Acthar |
| Amgen INC. | $133.25 | 2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $130.60 | 2020-2024 | Dupixent |
| La Jolla Pharmaceutical Company | $128.41 | 2021-2022 | |
| Genentech USA, INC. | $128.00 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $117.77 | 2019 | |
| Grifols USA, LLC | $102.07 | 2021-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $90.01 | 2020-2025 | |
| Body Vision Medical INC. | $84.70 | 2024 | Lungvision |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72.04 | 2021-2024 | Glassia |
| Jazz Pharmaceuticals INC. | $51.29 | 2021-2022 | |
| Verona Pharma, INC. | $49.24 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $36.80 | 2021 | |
| Pulmonx Corporation | $35.10 | 2020-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Novartis Pharmaceuticals Corporation | $32.28 | 2019-2021 | |
| United Therapeutics Corporation | $31.94 | 2024 | Tyvaso |
| Allergan, INC. | $30.83 | 2020 | |
| Merck Sharp & Dohme LLC | $30.10 | 2021-2022 | |
| Abbvie INC. | $28.73 | 2021 | |
| Baxter Healthcare | $26.94 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Paratek Pharmaceuticals, INC. | $26.85 | 2023 | Nuzyra |
| Intuitive Surgical, INC. | $25.00 | 2023 | Da Vinci Surgical System |
| Tactile Systems Technology INC | $19.59 | 2025 | Nimbl, Flexitouch Plus |
| Philips North America LLC | $18.91 | 2021 | |
| Viatris Specialty LLC | $17.50 | 2025 | Yupelri |
| Advanced Respiratory, INC | $14.25 | 2021 | |
| Novo Nordisk INC | $13.68 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phalgoon Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.